Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

1,664.00INR
6:28am EDT
Change (% chg)

Rs-32.70 (-1.93%)
Prev Close
Rs1,696.70
Open
Rs1,700.00
Day's High
Rs1,711.00
Day's Low
Rs1,658.65
Volume
738,391
Avg. Vol
1,776,665
52-wk High
Rs2,115.00
52-wk Low
Rs1,107.30

LUPN.NS

Chart for LUPN.NS

About

Lupin Limited is an India-based transnational pharmaceutical company. The Company is engaged in the producing, developing and marketing of branded and generic formulations, and active pharmaceutical ingredients (APIs). The Company's brands include Gluconorm, Tonact, Rablet, Budamate, Telekast, Rcinex, Clopitab, Telista, Ramistar... (more)

Overall

Beta: 0.35
Market Cap(Mil.): Rs763,396.31
Shares Outstanding(Mil.): 449.93
Dividend: 7.50
Yield (%): 0.44

Financials

  LUPN.NS Industry Sector
P/E (TTM): 33.28 37.25 40.68
EPS (TTM): 50.98 -- --
ROI: -- 16.52 15.78
ROE: -- 17.30 16.82
Search Stocks

Deals of the day-Mergers and acquisitions

July 23 - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:

23 Jul 2015

India's Lupin looks to revive U.S. growth with $880 million GAVIS deal

MUMBAI - Lupin Ltd , India's third-largest drugmaker by sales, is buying U.S. peer GAVIS Pharmaceuticals LLC for $880 million in its largest ever acquisition, seeking to revive its flagging growth in the United States, its largest market.

23 Jul 2015

Lupin looks to revive U.S. growth with $880 mln GAVIS deal

MUMBAI - Lupin Ltd , India's third-largest drugmaker by sales, is buying U.S. peer GAVIS Pharmaceuticals LLC for $880 million in its largest ever acquisition, seeking to revive its flagging growth in the United States, its largest market.

23 Jul 2015

UPDATE 2-India's Lupin looks to revive U.S. growth with $880 mln GAVIS deal

* Q1 U.S. total sales down 31 pct (Adds management comments, details)

23 Jul 2015

India's Lupin buys U.S. generics firm Gavis for $880 mln

MUMBAI, July 23 - Lupin Ltd, India's fourth-largest drugmaker by sales, said it had agreed to buy privately-held generics company Gavis for $880 million to strengthen its presence in its largest market, the United States.

23 Jul 2015

UPDATE 1-India expands medicine price control list to include 39 more drugs

* Abbott, GSK, Lupin and Ipca among firms affected (Adds details on government's position, results of new study )

16 Jul 2015

Indian shares extend recent gains to hit 2-1/2-month highs

MUMBAI, July 3 - Indian shares hit their highest in 2-1/2 months on Friday and posted their third consecutive weekly gain given a Greece default is seen as factored in, while better-than-expected progress of the monsoon also helped sentiment.

03 Jul 2015

India's Lupin, Cipla bid for UCB's US generic drugs portfolio - Bloomberg

MUMBAI, June 1 - Indian generic drugmakers Lupin Ltd and Cipla Ltd are among the companies bidding for top Belgian drugmaker UCB SA's U.S. generic drugs business, Bloomberg reported on Monday, citing unnamed people with knowledge of the matter.

01 Jun 2015

BRIEF-India's BSE to add Lupin to Sensex index, dropping Tata Power

* India's BSE says announces reconstitution of benchmark Sensex index

22 May 2015

BRIEF-Indian drugmaker Lupin to buy Brazil's Medquímica

* Says acquired 100 percent stake in Medquímica Indústria Farmacêutica S.A., Brazil

13 May 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Wright Reports
$75.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Motilal Oswal Securities Ltd.
$161.00
Provider : Spark Capital Advisors(India) Private Limited
$81.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks